Schwarze Juan-Enrique, Venetis Christos, Iniesta Silvia, Falla Edel, Lukyanov Vasily, de Agustin Calvo Elena, D Hooghe Thomas, Roeder Claudia, Matorras Roberto
Merck Healthcare KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany.
Centre for Big Data Research in Health & School of Women's and Children's Health, UNSW Medicine & Health, Sydney, NSW, 2052, Australia; IVF Australia, Level 3, 15 Bowden Street, Alexandria, NSW, 2015, Australia.
Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt B):203-216. doi: 10.1016/j.bpobgyn.2022.01.011. Epub 2022 Feb 8.
This study compared the cost per live birth and cost-effectiveness of the originator recombinant human follicle-stimulating hormone follitropin alfa (r-hFSH-alfa) and r-hFSH-alfa biosimilars for ovarian stimulation prior to assisted reproductive technology treatment in Spain. A decision tree model was developed, comprising pregnancy and live birth for one treatment cycle with fresh embryo transfer. Clinical inputs were based on a recent meta-analysis by Chua et al. [4]. Cost inputs were extracted from publicly available Spanish sources. The costs per live birth were lower with originator r-hFSH-alfa (€18,138) versus r-hFSH-alfa biosimilars (€20,377). The incremental cost-effectiveness ratio was €7208 for originator r-hFSH-alfa versus biosimilars. Drug acquisition costs for originator r-hFSH-alfa represented 10.5% of total costs in the base case analysis, and 6.2% in a treatment cycle resulting in live birth with one fresh embryo transfer. Results from the sensitivity analyses confirmed the robustness of the findings.
本研究比较了西班牙辅助生殖技术治疗前，原研重组人促卵泡激素α（r-hFSH-α）和r-hFSH-α生物类似药用于卵巢刺激的每活产成本和成本效益。构建了一个决策树模型，涵盖一个新鲜胚胎移植治疗周期的妊娠和活产情况。临床数据基于Chua等人[4]最近的一项荟萃分析。成本数据取自西班牙公开可用的资料来源。原研r-hFSH-α的每活产成本（18,138欧元）低于r-hFSH-α生物类似药（20,377欧元）。原研r-hFSH-α与生物类似药相比，增量成本效益比为7208欧元。在基础病例分析中，原研r-hFSH-α的药品购置成本占总成本的10.5%，在一次新鲜胚胎移植导致活产的治疗周期中占6.2%。敏感性分析结果证实了研究结果的稳健性。
